Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Beractant adverse reaction |
Causative agent (attribute) |
True |
Beractant (substance) |
Inferred relationship |
Some |
1 |
Allergy to beractant (finding) |
Causative agent (attribute) |
False |
Beractant (substance) |
Inferred relationship |
Some |
|
Beractant 200mg/8mL suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Beractant (substance) |
Inferred relationship |
Some |
|
Product containing beractant (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Beractant (substance) |
Inferred relationship |
Some |
1 |
Beractant 100mg intratracheal suspension 4mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Beractant (substance) |
Inferred relationship |
Some |
|
Allergy to beractant (finding) |
Causative agent (attribute) |
True |
Beractant (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely phospholipid (as beractant) 200 milligram/8 milliliter conventional release suspension for endotracheopulmonary instillation bottle |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Beractant (substance) |
Inferred relationship |
Some |
1 |
Product containing beractant in pulmonary dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Beractant (substance) |
Inferred relationship |
Some |
1 |
Product containing only beractant (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Beractant (substance) |
Inferred relationship |
Some |
1 |
Product containing only beractant in pulmonary dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Beractant (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely phospholipid (as beractant) 25 milligram/1 milliliter conventional release suspension for endotracheopulmonary instillation (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Beractant (substance) |
Inferred relationship |
Some |
1 |